Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia (L2009-03)

Lescuyer Laboratory

Status

Unknown

Conditions

Fibromyalgia

Treatments

Dietary Supplement: PLACEBO

Dietary Supplement: PERMEAPROTECT

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01469936

2010-A00971-38

Details and patient eligibility

About

Fibromyalgia is a medical disorder characterized by chronic widespread pain, and a heightened and painful response to pressure. Fibromyalgia symptoms are not restricted to pain, leading to the use of the alternative term fibromyalgia syndrome for the condition. Other symptoms include functional gastrointestinal pain and discomfort.

The origin of these symptoms is not yet known, and a few hypotheses have been stated. One of the supposed mechanisms that may lead to gastrointestinal hypersensitivity is a chronic, low-grade, intestinal inflammation due to an increased intestinal permeability.

In this study, we hypothesise that the food supplement PERMEAPROTECT (that contains, amongst other nutrients, glutamine and curcumin) contributes to reducing the intestinal permeability and low-grade inflammation, thus improving gastrointestinal quality of life.

Full description

Patients diagnosed with fibromyalgia will enter the study and follow a run-in phase during which they will all be supplemented with prebiotics, probiotics and grape fruit seed extract for 5 weeks :

Patients that do not present a satisfactory relief of gastrointestinal symptoms (patient subjective evaluation) will enter the randomised phase after 2 weeks +/- 1 week, at day D0.
Patients that do present a satisfactory relief of gastrointestinal symptoms (patient subjective evaluation) will exit the study at that point, and follow their usual medical care.

Patients that enter the randomised phase will be supplemented with either PERMEAPROTECT or a PLACEBO, for 5 weeks +/- 1 week. Patients will then follow a 2 weeks +/- 1 week of wash-out, during which no supplementation will be made.

Measures of the outcomes will be made :

at Day 0 (beginning of supplementation).
at Day 35 (+/- 7) (end of supplementation).
at Day 49 (+/- 7) (end of follow-up, end of study)

Enrollment

40 patients

Sex

Female

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

BMI between 18.5 and 30 kg/m²
Diagnosed fibromyalgia, according to the American College of Rheumatology criteria
Functional bowel discomfort or pain
Pre-menopausal woman with active contraception or post-menopausal woman

Exclusion criteria

Allergy to one (or more) component(s) of verum or placebo.
Disease or disease treatment that could interfere with the efficacy evaluation.
Treatment with statin (or HMG-CoA reductase inhibitors) associated with adverse effect
Treatment with Coumadin (or any other Vitamin K antagonists)
Severe depression (Beck Depression Inventory score > 16)
Recent (during the previous month) change(s) in probiotic intake (including fermented milk, kefir, ...)
History of major gastrointestinal surgery or inflammatory bowel disease
Pregnant, breastfeeding or intention of pregnancy in the next three month